Recommended
product-img
  • Products
  • Discover MP Targets
  • Discover Research Areas
  • mProX™ Human FCGR3A Stable Cell Line

    [CAT#: S01YF-1023-PY158]
    Product Category:
    Membrane Protein Stable Cell Lines
    Subcategory:
    Fc Receptor Cell Lines

    Datasheet MSDS Request COA

    Certificate of Analysis Lookup
    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
    Lot Number

    Made to Order Inquiry

    Inquiry
    Host Cell Type:
    Membrane Protein Engineering:
    Fluorescent Marker:
    Resistance:
    Deliverable:

    Product Information

    Target Family
    Fc Receptor
    Target Protein Species
    Human
    Host Cell Type
    HEK293;CHO-K1
    Target Classification
    Fc Receptor Cell Lines
    Target Research Area
    Infectious Research
    Related Diseases
    Immunodeficiency 20; Herpes Zoster
    Gene ID
    Human:2214
    UniProt ID
    Human:P08637

    Product Properties

    Biosafety Level
    Level 1
    Activity
    Yes
    Quantity
    10⁶ cells per vial
    Applications
    FCGR3A, also known as CD16a, is a gene that has been studied in various medical contexts. In a study on lung squamous cell carcinoma (LUSC), researchers constructed a prognostic model and miRNA-mRNA regulatory network using data from the cancer genome atlas (TCGA) database. They identified FCGR3A as one of the hub-targeted mRNAs in the protein-protein interaction (PPI) network, which provided insights into the molecular pathogenesis of LUSC and potential applications in clinical diagnosis and treatment. Another study focused on gene copy number estimation and found that FCGR3A showed a higher concordance compared to other methods, indicating its potential use in this context. In a study on pemphigus vulgaris and pemphigus foliaceus, FCGR3A alleles/genotypes were found to be differentially expressed, suggesting a potential role in the pathogenesis of these diseases. Finally, in a study on diabetic retinopathy (DR), FCGR3A was identified as one of the hub genes associated with immune infiltration in the retina of DR patients, highlighting its potential as a diagnostic marker for this condition. Overall, FCGR3A has been implicated in various diseases and has potential applications in prognosis, gene copy number estimation, autoimmune disorders, and retinal diseases.

    Protocols

    Please visit our protocols page.

    Customer Reviews

    There are currently no Customer reviews or questions for mProX™ Human FCGR3A Stable Cell Line (S01YF-1023-PY158). Click the button above to contact us or submit your feedback about this product.

    FAQ

    chat Skyler Davis (Verified Customer)

    Is FCGR3A a potential biomarker for tumor immunity? May 27 2020

    chat Patrick Liam (Creative Biolabs Scientific Support)

    FCGR3A may serve as a biomarker associated with tumor immune infiltration levels and drug sensitivity, making it a promising candidate for cancer detection and therapy. May 27 2020

    chat Jordan Brown (Verified Customer)

    How does FCGR3A affect the treatment of neuromyelitis optica spectrum disorder? Dec 31 2021

    chat Patrick Liam (Creative Biolabs Scientific Support)

    Mutations in the FCGR3A genotype might influence the effectiveness of treatments like rituximab in neuromyelitis optica spectrum disorder. Dec 31 2021

    Published Data

    Fig.1 The expression of CD16B/A was observed on both polymorphonuclear cells and HEK-293T cells.

    The requirement for cell surface expression of the transmembrane CD16BA receptor is dependent on its association with FcϵR1γ or CD247 adaptor molecules. In our experiments, HEK-293T cells were subjected to transfection with plasmids driving the expression of various receptors and adaptor molecules, followed by the evaluation of CD16 cell surface expression using flow cytometry and western blot analysis. Remarkably, the results consistently revealed that over 40% of the transfected cells exhibited CD16 expression on their cell surface, except when CD16A or CD16B/A were transfected alone, in which cases CD16 staining was only observed in a mere 1.17% and 0.84% of the cells, respectively.

    Ref: Moraru, Manuela, et al. "FCGR Genetic Variation in Two Populations From Ecuador Highlands-Extensive Copy-Number Variation, Distinctive Distribution of Functional Polymorphisms, and a Novel, Locally Common, Chimeric FCGR3B/A (CD16B/A) Gene." Frontiers in immunology 12 (2021): 615645.

    Pubmed: 34108956

    DOI: 10.3389/fimmu.2021.615645

    Research Highlights

    Zhao, Lun. et al. "Construction of Prognostic Model and miRNA-mRNA Regulatory Network for Lung Squamous Cell Carcinoma." Alternative therapies in health and medicine, 2023.
    The purpose of this paper was to construct a prognostic model, miRNA-mRNA regulatory network, and protein-protein interaction (PPI) network for lung squamous cell carcinoma (LUSC) using data from the Cancer Genome Atlas (TCGA) database. Data containing 19962 mRNA transcripts (502 LUSC and 51 normal control (NC) samples) and 2205 miRNA transcripts (478 LUSC and 45 NC samples) from the TCGA database were downloaded and analyzed. 389 differentially expressed miRNAs (DE-miRNAs), including 305 upregulated and 84 down-regulated DE-miRNAs, were obtained. 7 prognosis-related DE-miRNAs (PDE-miRNAs) were identified through Cox regression analysis, and a prognostic model consisting of three PDE-miRNAs (hsa-miR-4746-5p, hsa-miR-556-3p, and hsa-miR-489-3p) was optimized. The survival rates of patients with high and low expression of the three PDE-miRNAs and those in the high-risk and low-risk groups in the prognosis model were significantly different. The constructed miRNA-mRNA regulatory network and PPI network of targeted mRNAs showed the relationship and interaction between DE-miRNAs and targeted mRNAs. These results suggest that the prognosis model has the potential to accurately predict LUSC patients, and the miRNA-mRNA regulatory network and PPI network provide valuable insights into the molecular pathogenesis of LUSC for clinical diagnosis and treatment strategies.
    Zhao, Lun. et al. "Construction of Prognostic Model and miRNA-mRNA Regulatory Network for Lung Squamous Cell Carcinoma." Alternative therapies in health and medicine, 2023.
    Pubmed: 37856813   DOI: No

    Pajuste, Fanny-Dhelia; Re, Maido. "GeneToCN: an alignment-free method for gene copy number estimation directly from next-generation sequencing reads." Scientific reports, 2023.
    A novel computational approach called GeneToCN has been developed to analyze genomes, specifically focusing on segmental copy number variations encompassing entire genes, some of which exhibit multiallelic patterns. GeneToCN assesses gene-specific k-mer frequencies in FASTQ files, enabling precise gene copy number inference. Validation of this method involved amy1, amy2a, and amy2b genes using ddPCR data, revealing a robust correlation (R = 0.99) between GeneToCN predictions and experimental results. Additional testing on FCGR3 genes highlighted its superior performance for FCGR3A compared to other methods but decreased accuracy for FCGR3B. Furthermore, GeneToCN demonstrated consistency across different sequencing technologies, including Illumina, PacBio, and Oxford Nanopore, in predicting copy numbers for SMN, NPY4R, and LPA Kringle IV-2 domain genes. These findings align with previous research and indicate its potential applicability across diverse sequencing platforms.
    Pajuste, Fanny-Dhelia; Re, Maido. "GeneToCN: an alignment-free method for gene copy number estimation directly from next-generation sequencing reads." Scientific reports, 2023.
    Pubmed: 37853040   DOI: 10.1038/s41598-023-44636-z

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR CLINICAL PROCEDURES" For licensing inquiries, please contact
    Send Inquiry Send Inquiry
    Inquiry Basket
    compare

    Go to compare